New York State Common Retirement Fund Acquires 2,082 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

New York State Common Retirement Fund boosted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,564 shares of the company’s stock after purchasing an additional 2,082 shares during the quarter. New York State Common Retirement Fund’s holdings in Sana Biotechnology were worth $166,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in SANA. TD Asset Management Inc boosted its stake in Sana Biotechnology by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 362,652 shares of the company’s stock valued at $1,403,000 after purchasing an additional 181,326 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Sana Biotechnology by 13.1% during the 3rd quarter. Principal Financial Group Inc. now owns 42,664 shares of the company’s stock worth $165,000 after purchasing an additional 4,928 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Sana Biotechnology during the third quarter valued at approximately $52,000. Barclays PLC raised its stake in shares of Sana Biotechnology by 3.1% in the third quarter. Barclays PLC now owns 205,567 shares of the company’s stock valued at $797,000 after purchasing an additional 6,096 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ bought a new position in Sana Biotechnology in the third quarter worth $1,215,000. Institutional investors own 88.23% of the company’s stock.

Analyst Upgrades and Downgrades

SANA has been the subject of a number of recent research reports. JMP Securities increased their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “market outperform” rating in a research note on Friday, March 1st. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Sana Biotechnology in a research note on Thursday, May 9th.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA opened at $8.73 on Friday. Sana Biotechnology, Inc. has a 52-week low of $2.74 and a 52-week high of $12.00. The business has a fifty day moving average of $8.98 and a two-hundred day moving average of $6.72. The stock has a market cap of $1.93 billion, a PE ratio of -5.71 and a beta of 1.62.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. During the same quarter last year, the business earned ($0.40) earnings per share. Analysts predict that Sana Biotechnology, Inc. will post -1.15 earnings per share for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.